Article
Oncology
Chuntao Li, Bo Chen, Junxia Zhang, Jingxuan Yang, Muzi Guo, Yu Ren, Zhijun Zhou, Kar-Ming Fung, Min Li, Liyang Zhang, Zhixiong Liu
Summary: SEM1 is highly expressed in gliomas and correlated with malignant features and poor prognosis. SEM1 plays a critical role in the proliferation, apoptosis, invasion, and migration of glioma cells through regulating the PI3K-Akt pathway. The SEM1 malignant regulatory network shows significant importance for the prognosis and treatment of gliomas.
Article
Oncology
Chunhong Wang, Haiyang Su, Rui Cheng, Hongming Ji
Summary: The study demonstrated that high expression of SPAG5 in glioma patients is associated with poor prognosis. Knockdown of SPAG5 can inhibit proliferation, migration, and invasion of glioma cells, promote apoptosis, and is associated with the expression of CDH2.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Lei Wang, Yan Liu, Zhengtao Yu, Jianwu Gong, Zhiyong Deng, Nianjun Ren, Zhe Zhong, Hao Cai, Zhi Tang, Haofeng Cheng, Shuai Chen, Zhengwen He
Summary: The study investigates the pathogenesis and potential molecular markers of glioma by examining the differential expression of miRNA and mRNA. Several miRNAs and mRNAs were identified as having significant impact on glioma cell behavior, with miR-139-5p/GABRA1 axis suggested as a novel therapeutic target.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Cheng-Chen Zhang, Ting Wu, Li Guan, Yu-Jue Wang, Rui-Qin Yao, Dian-Shuai Gao, Feng Li
Summary: This study demonstrates that BP-1-102 can inhibit the proliferation, invasion, and migration abilities of glioma cells, induce cell apoptosis, and reduce neurosphere formation. These effects are achieved through the reduction of STAT3 phosphorylation and its nuclear translocation by BP-1-102.
CELL BIOCHEMISTRY AND BIOPHYSICS
(2022)
Review
Cell Biology
Kang Hu, Qing-Kang Zheng, Rui-Jie Ma, Chao Ma, Zhi-Gang Sun, Nan Zhang
Summary: Kruppel-like factor 6 (KLF6) is a well-studied member of the SP/KLF transcription factor family, playing a pivotal role in regulating cellular processes. Its splice variant 1 (KLF6-SV1) is involved in tumor occurrence and development and has the potential to become a new target for molecular targeted therapy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Medicine, Research & Experimental
Yunsheng Liu, Xiangping Xu, Han Tang, Yuchen Pan, Bing Hu, Guodong Huang
Summary: The study found that RA, as a Fyn inhibitor, has anti-tumor effects in U251 and U343 glioma cells, significantly suppressing cell proliferation, migration, and invasion, and inducing apoptosis. Additionally, RA exerts its cytotoxicity by modulating the PI3K/Akt/NF-kappa B signaling pathway.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
(2021)
Article
Cell Biology
Xiaomin Cai, Wenjin Qiu, Mengshu Qian, Shuang Feng, Chenghao Peng, Jiale Zhang, Yi Wang, Yuhai Wang
Summary: CFI is overexpressed in glioma and is associated with poor outcomes, serving as a potential prognostic biomarker and driving malignant progression in glioma.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Medicine, Research & Experimental
Min Gao, Tianyi Yu, Dan Liu, Yan Shi, Peilang Yang, Jie Zhang, Jizhuang Wang, Yan Liu, Xiong Zhang
Summary: The study investigated the effect of miR-1-3p on endothelial cells during sepsis, finding that miR-1-3p inhibits cell proliferation, promotes apoptosis and cytoskeleton contraction by targeting SERP1, leading to dysfunction of endothelial cells and weakening vascular barrier function. MiR-1-3p and SERP1 may be promising therapeutic candidates for sepsis-induced lung injury.
Article
Cell Biology
Yuqing Duan, Yunlong Jia, Jiali Wang, Tianxu Liu, Zishuo Cheng, Meixiang Sang, Wei Lv, Jing Qin, Lihua Liu
Summary: The study reveals that upregulated lncRNA DGCR5 promotes proliferation, migration, and invasion of ESCC cells while inhibiting apoptosis. DGCR5 directly binds to SRSF1, increasing its stability and initiating important isoform switch of Mcl-1. Cell-derived xenograft model confirms DGCR5's role in facilitating ESCC tumorigenesis.
CELL DEATH & DISEASE
(2021)
Article
Biotechnology & Applied Microbiology
Jingya Wang, Peng Ren, Zhirui Zeng, Li Ma, Yunjun Li, Hongmei Zhang, Wenzhi Guo
Summary: TSPO promotes the nuclear-cytoplasmic shuttling of HUR, leading to increased mRNA stability of MAPKAPK3 and promoting the proliferation and mobility of glioma cells.
Article
Oncology
Jiangfeng Du, Ji Li, Jianjun Tan, Yi Yan
Summary: This study investigated the effect of scutellarin on the proliferation of glioma cells and found that it works by regulating the expression of miR-15a.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2023)
Article
Multidisciplinary Sciences
Huey-Miin Chen, Justin A. MacDonald
Summary: The study identified a module containing 151 genes that was significantly correlated with lymphatic invasion in colon cancer, with DAPK3 identified as the pseudohub of the module. High expression of DAPK3 was significantly associated with greater lymphatic invasion and poor overall survival. Gene ontology analysis suggested that the module is involved in tumor cell survival, migration, and epithelial-mesenchymal transformation.
Article
Plant Sciences
Kay Zin Kyaw, Woong Sub Byun, Yern-Hyerk Shin, Thanh-Hau Huynh, Ji Yun Lee, Eun Seo Bae, Hyen Joo Park, Dong-Chan Oh, Sang Kook Lee
Summary: Piceamycin (1), a macrocyclic lactam isolated from the silkworm's gut, has been found to possess antibacterial activity. This study investigates the potential anticancer activity of 1 and its underlying mechanisms in colorectal cancer (CRC) cells. The results show that 1 inhibits CRC cell growth by upregulating NDRG1, inducing cell cycle arrest and apoptosis, and inhibiting cell migration. The disruption of the interaction between NDRG1 and c-Myc is also observed. This suggests that 1 may serve as a potential candidate for CRC treatment by regulating NDRG1-mediated functionality.
JOURNAL OF NATURAL PRODUCTS
(2022)
Article
Oncology
Ge Zhang, Guanghui Ren, Xin Zhao, Haibo Wang
Summary: This study explored the roles of Aurora Kinase A in human glioma progression and found that silencing Aurora A inhibited cell proliferation, induced cell cycle arrest and apoptosis, as well as suppressed tumor growth in vivo. The results suggest that Aurora A can be a potential therapeutic target for glioblastoma.
Article
Multidisciplinary Sciences
Irati Macaya, Marta Roman, Connor Welch, Rodrigo Entrialgo-Cadierno, Marina Salmon, Alba Santos, Iker Feliu, Joanna Kovalski, Ines Lopez, Maria Rodriguez-Remirez, Sara Palomino-Echeverria, Shane M. Lonfgren, Macarena Ferrero, Silvia Calabuig, Iziar A. Ludwig, David Lara-Astiaso, Eloisa Jantus-Lewintre, Elizabeth Guruceaga, Shruthi Narayanan, Mariano Ponz-Sarvise, Antonio Pineda-Lucena, Fernando Lecanda, Davide Ruggero, Purvesh Khatri, Enrique Santamaria, Joaquin Fernandez-Irigoyen, Irene Ferrer, Luis Paz-Ares, Matthias Drosten, Mariano Barbacid, Ignacio Gil-Bazo, Silve Vicent
Summary: Drug combinations are essential for overcoming resistance to targeted therapies in cancer treatment. By utilizing a gene signature-driven drug repurposing approach and a pairwise pharmacological screen, the authors identified a synergistic drug combination for KRAS-mutated lung adenocarcinoma. The combination treatment shows cytotoxic response and involves inhibition of the PKC inhibitor target AURKB.
NATURE COMMUNICATIONS
(2023)
Article
Immunology
Jingwei Zhang, Zeyu Wang, Xun Zhang, Ziyu Dai, Wen Zhi-Peng, Jing Yu, Yun Peng, Wantao Wu, Nan Zhang, Peng Luo, Jian Zhang, Zaoqu Liu, Songshan Feng, Hao Zhang, Quan Cheng
Summary: CD147 plays an important role in promoting tumor proliferation and inhibiting cancer cell apoptosis in the tumor microenvironment. The study reveals the prognostic value and immune characteristics of CD147 in multiple cancer types. In addition, the study explores the expression of CD147 on different cell types in the tumor microenvironment and identifies potential therapeutic strategies for tumor immunotherapy based on CD147.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Rui Chen, Hao Zhang, Wantao Wu, Shuyu Li, Zeyu Wang, Ziyu Dai, Zaoqu Liu, Jian Zhang, Peng Luo, Zhiwei Xia, Quan Cheng
Summary: In this study, a large-scale bioinformatics analysis was conducted to explore the prognostic and predictive value of antigen presentation machinery (APM) signature in gliomas. The APM signature and risk score based on it showed promising performance in stratifying survival and predicting tumorigenic factors in glioma patients. The APM signature-based risk score was also validated in external cohorts and successfully predicted immunotherapy response. This study provides insights into the potential clinical applications of APM signature and risk score in gliomas.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Xizhe Li, Ziyu Dai, Xianning Wu, Nan Zhang, Hao Zhang, Zeyu Wang, Xun Zhang, Xisong Liang, Peng Luo, Jian Zhang, Zaoqu Liu, Yanwu Zhou, Quan Cheng, Ruimin Chang
Summary: A new autophagy-based signature has been identified that can predict the prognosis of LUAD patients, and this ATscore has potential applicative value in predicting the efficiency of checkpoint therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Songshan Feng, Jing Li, Fan Fan, Zeyu Wang, Qian Zhang, Hao Zhang, Ziyu Dai, Xun Zhang, Peng Luo, Zaoqu Liu, Jian Zhang, Zhuoyi Liu, Quan Cheng
Summary: This study aimed to explore prognostic factors and optimal therapeutic strategy in elderly patients with MM. The findings suggest that radical tumor resection does not provide survival benefit compared to subtotal resection in elderly patients. Postoperative radiotherapy also does not significantly affect survival in this population.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Yuanyuan Liu, Jingwei Zhang, Zeyu Wang, Xun Zhang, Ziyu Dai, Wantao Wu, Nan Zhang, Zaoqu Liu, Jian Zhang, Peng Luo, Zhipeng Wen, Jing Yu, Hao Zhang, Tubao Yang, Quan Cheng
Summary: This study systematically explored the prognostic and immune profile of VSIR in the tumor microenvironment of 33 cancers, and found that it is strongly correlated with the clinical outcome and tumor immunity in multiple cancer types.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Neurosciences
Hao Zhang, Yifan Wang, Yihan Zhao, Tao Liu, Zeyu Wang, Nan Zhang, Ziyu Dai, Wantao Wu, Hui Cao, Songshan Feng, Liyang Zhang, Quan Cheng, Zhixiong Liu
Summary: The study reveals that PTX3 is upregulated in glioblastoma and is closely related to other immune-related genes in the tumor microenvironment. PTX3 is involved in regulating macrophage migration, inflammation-resolving polarization, and can predict immunotherapy response.
CNS NEUROSCIENCE & THERAPEUTICS
(2022)
Article
Oncology
Tianqi Gu, Aimin Jiang, Chaozheng Zhou, Anqi Lin, Quan Cheng, Zaoqu Liu, Jian Zhang, Peng Luo
Summary: This study aims to determine the safety of immune checkpoint inhibitors combined with the anti-angiogenesis drug bevacizumab through a large-scale retrospective analysis of adverse drug reactions (ADRs). The risk of ADRs such as interstitial lung disease, hypertension, and gastrointestinal bleeding was found to be elevated in patients receiving combination therapy.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Hao Zhang, Nan Zhang, Ziyu Dai, Zeyu Wang, Xun Zhang, Xisong Liang, Liyang Zhang, Songshan Feng, Wantao Wu, Weijie Ye, Jian Zhang, Peng Luo, Zaoqu Liu, Quan Cheng, Zhixiong Liu
Summary: This study systematically evaluated the relationship between the metabolic pattern of gliomas and patient survival outcome and immune activity. The results identified three distinct metabolic phenotypes and revealed the important role of hyaluronic acid (HA) in glioma proliferation, progression, invasion, and immune infiltration. HA was found to potentially regulate macrophage recruitment, M2 polarization, and the expression of PD-L1 in gliomas.
MOLECULAR ONCOLOGY
(2022)
Review
Neurosciences
Jingwei Zhang, Zeyu Wang, Hao Zhang, Shuwang Li, Jing Li, Hongwei Liu, Quan Cheng
Summary: Ischemic and hemorrhagic stroke are the leading causes of disability and death globally. Lipocalin 2 (LCN2) plays a vital role in brain injury after stroke, but its specific mechanism and involvement of primary receptors remain unclear. Further research is needed to explore LCN2-induced brain damage and identify therapeutic targets.
FRONTIERS IN MOLECULAR NEUROSCIENCE
(2022)
Article
Immunology
Zicheng Wang, Xisong Liang, Hao Zhang, Zeyu Wang, Xun Zhang, Ziyu Dai, Zaoqu Liu, Jian Zhang, Peng Luo, Jiarong Li, Quan Cheng
Summary: This study aimed to investigate the effects of hypoxia and angiogenesis on gastric cancer and establish a related model. The results showed that the model could accurately predict patient survival and was associated with the staging of gastric cancer. Various cancer-associated pathways and macrophage-related regulations were upregulated in the high-HARM group. The high-HARM group also exhibited higher immune levels and increased infiltration of M2 macrophages and cancer-associated fibroblasts. Additionally, globally upregulated immune checkpoints and higher TIDE scores were observed in the high-HARM group. Eight drugs with lower IC50 in the high-HARM group were identified as potential drugs for HARM-targeted therapy.
JOURNAL OF IMMUNOLOGY RESEARCH
(2022)
Article
Immunology
Songshan Feng, Xisong Liang, Jing Li, Zeyu Wang, Hao Zhang, Ziyu Dai, Peng Luo, Zaoqu Liu, Jian Zhang, Xiaoxiong Xiao, Quan Cheng
Summary: Immunogenic cell death (ICD) is an important factor in tumor progression and therapeutic response. This study identifies ICD-related genes and constructs a risk signature that can predict prognosis and response to immune checkpoint blockade (ICB) treatment in glioblastoma (GBM) patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
He Li, Zhao-Yi Liu, Yong-Chang Chen, Xiao-Ye Zhang, Nayiyuan Wu, Jing Wang
Summary: This study investigated the prognostic value of immune-related lncRNAs in ovarian cancer patients and constructed an immune-related lncRNA prognostic signature that can predict patients' survival prognosis and potentially facilitate personalized counseling for immunotherapy and chemotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Medicine, Research & Experimental
Hao Zhang, Ruixuan Wang, Zeyu Wang, Wantao Wu, Nan Zhang, Longbo Zhang, Jason Hu, Peng Luo, Jian Zhang, Zaoqu Liu, Songshan Feng, Yun Peng, Zhengzheng Liu, Quan Cheng
Summary: PTX3 is an acute-phase protein that regulates innate immunity, inflammation, angiogenesis, and tissue remodeling. It has dual roles in oncogenesis and is involved in the occurrence and development of non-cancerous diseases. PTX3 expression is influenced by various factors and may serve as a potential biomarker for prognosis, activity, and severity of diseases.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Cell Biology
Zeyu Wang, Ziyu Dai, Hao Zhang, Nan Zhang, Xisong Liang, Luo Peng, Jian Zhang, Zaoqu Liu, Yun Peng, Quan Cheng, Zhixiong Liu
Summary: In this study, we collected 73 GBM samples and found that the different subtypes of GBM have different prognoses. We also discovered the association between pyroptosis and tumor-microglia interaction and the tumor response to interferon-gamma. Based on pyroptosis-related genes, we grouped GBM samples into cluster 1 and cluster 2, with cluster 1 samples showing worse prognosis and a more complex immune landscape. Machine learning algorithms identified nutlin-3 as a potential treatment for cluster 1 samples.
CELL PROLIFERATION
(2023)
Article
Immunology
Rui Chen, Wantao Wu, Tao Liu, Yihan Zhao, Yifan Wang, Hao Zhang, Zeyu Wang, Ziyu Dai, Xiaoxi Zhou, Peng Luo, Jian Zhang, Zaoqu Liu, Li-Yang Zhang, Quan Cheng
Summary: This study suggests that mast cells play a potential effective prognostic factor in gliomas. Using mast cell-related genes, gliomas can be divided into clusters with distinct clinical and immunological characteristics, and cluster 1 has significantly lower survival probability than cluster 2. Additionally, the hypoxic and metabolic pathways are active in cluster 1, promoting tumor cell proliferation. By constructing a prognostic model and using machine learning, DRG2 was identified as a characteristic gene that can predict treatment response and survival outcome.
FRONTIERS IN IMMUNOLOGY
(2022)
